Indaptus Therapeutics, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Indaptus Therapeutics, Inc. (INDP) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.37 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-17
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$4.37M.
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$3.15M.
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$3.24M.
- Indaptus Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$3.01M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$4.37M 10-K · filed 2026-03-17 |
| 2024-12-31 | -$3.15M 10-K · filed 2026-03-17 |
| 2023-12-31 | -$3.24M 10-K · filed 2025-03-13 |
| 2022-12-31 | -$3.01M 10-K · filed 2024-03-13 |
| 2021-12-31 | -$1.62M 10-K · filed 2023-03-17 |
| 2020-12-31 | -$753.34K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |